Format

Send to

Choose Destination
See comment in PubMed Commons below
Cancer Prev Res (Phila). 2010 Nov;3(11):1375-8. doi: 10.1158/1940-6207.CAPR-10-0216.

Chemoprevention of pancreatic cancer: ready for the clinic?

Author information

  • 1Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 426, Houston, TX 77030, USA.

Abstract

Advances in our molecular, clinical, and epidemiologic understanding of the risk and development of pancreatic cancer offer hope for preventing this disease, which is largely intractable once developed. This perspective on provocative, genetically engineered mouse model work reported by Mohammed et al. (beginning on page 1417 in this issue of the journal) examines the prospects for pancreatic cancer chemoprevention with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI). Despite having limited value in advanced pancreatic cancer, EGFR TKIs show promise in the setting of early pancreatic carcinogenesis.

PMID:
21084259
PMCID:
PMC3051830
DOI:
10.1158/1940-6207.CAPR-10-0216
[PubMed - indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire Icon for PubMed Central
    Loading ...
    Support Center